Pharmacologic inhibition of the CD40-TRAF6 pathway using the small molecule inhibitor (SMI) 687002 ameliorated obesity-related metabolic complications and type 2 diabetes [9, 19, 20]. The gene discussed is TRAF6; the disease is obesity due to melanocortin 4 receptor deficiency.